Hematopoiesis News

Hematopoiesis News is an online resource that provides updates on the latest research in the fields of hematopoiesis, blood, and bone marrow disorders.

Subscribe|Follow Us On

Targeting ZMIZ1 Induces Differentiation in Acute Myeloid Leukemia via Chromatin Remodeling

May 26, 2026

[Signal Transduction and Targeted Therapy] Researchers identified Zinc finger MIZ domain-containing protein 1 (ZMIZ1) as a previously unrecognized transcriptional co-regulator that enforces differentiation blockade in AML from a targeted CRISPR-Cas9 screen.

A Kinetics-Based Model of Haematopoiesis Reveals Extrinsic Regulation of Skewed Lineage Output from Stem Cells

May 26, 2026

[Nature Cell Biology] By performing single-cell transplantations of over 1,000 highly purified murine long-term HSCs combined with in-depth phenotyping of their clonal progeny, scientists defined kinetics-based reconstitution parameters which aligned HSCs into a single hierarchical trajectory reflective of functional potency.

Stag2 dependent chromatin remodeling enforces the erythroid-specific Gata1 cistrome

May 26, 2026

[Blood] To understand the connection between chromatin accessibility and GATA1, investigators comprehensively studied erythropoiesis in Stag2∆ mice.

Copper Depletion Boosts CNS Leukemia Therapy by Inhibiting Nucleotide Synthesis through Impairment of Mitochondrial Complex IV Activity

May 26, 2026

[Nature Cancer] Scientists used a targeted in vivo CRISPR screen to identify nutritional dependencies of systemic and central nervous system acute lymphoblastic leukemia.

ZNF184 Negatively Regulates HR Repair and Predicts Poor Prognosis in Acute Lymphoblastic Leukemia

May 26, 2026

[Nucleic Acids Research] The authors identified a conserved set of seven zinc finger protein (ZNF) genes, including ZNF184, that are upregulated in acute lymphoblastic leukemia and exhibit dynamic expression patterns linked to disease progression.

Co-Occurring Clonal Hematopoiesis Exhibits Strong Selection and High Leukemia Risk

May 26, 2026

[Nature Communications] Researchers showed that clonal hematopoiesis (CH) co-occurrences are selected for in the aging population and identified CH clones with notable implications for future malignancy risk.

Utility of Flow Cytometric PAX5 Protein Detection for the Diagnosis of B-Cell Acute Lymphoblastic Leukemia

May 26, 2026

[Clinical Chemistry and Laboratory Medicine] Investigators validated the utility of flow cytometric detection of nPAX5 for the diagnosis of B-lymphoblastic leukemia, potentially enhancing diagnostic efficiency.

Phase Ib Study of ABBV-744, a Novel, Selective BET Inhibitor, As Monotherapy for Patients with Myelofibrosis

May 26, 2026

[Blood Advances] Scientists reported the outcomes of a multicenter, open-label Phase Ib study of ABBV-744 in patients with myelofibrosis who received ≥1 previous lines of therapy, including a Janus kinase inhibitors.

Phase II Study of the Lysine-Specific Demethylase 1 Inhibitor Bomedemstat for Essential Thrombocythemia

May 26, 2026

[Blood Advances] In a Phase II trial, participants with essential thrombocythemia who required cytoreduction and had inadequate response to, or were intolerant of, ≥1 standard therapy received bomedemstat at a starting dose of 0.6 mg/kg per day, titrated to achieve a target platelet count

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research

May 26, 2026

[Current Treatment Options in Oncology] The authors propose CRISPR-enhanced CARs and synthetic biology-based allogeneic systems to enhance the efficacy and accessibility of CAR-T therapy with the aim of moving the field of oncology towards durable cures.

US FDA Approves INQOVI® in Combination with Venetoclax, the First All-Oral Combination Treatment for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive...

May 26, 2026

[Taiho Oncology, Inc. (Business Wire)] Taiho Oncology, Inc. announced that the US FDA has approved INQOVI plus venetoclax as a treatment for adults with newly diagnosed acute myeloid leukemia who are 75 years or older or who are ineligible for intensive induction chemotherapy.

Dee and Jimmy Haslam Make $10 Million Transformational Investment in Blood Cancer Research and Treatments at the Oxford-Harrington Rare Disease Centre

May 12, 2026

[Oxford Harrington Rare Disease Centre] The Oxford-Harrington Rare Disease Centre has received $10 million in transformational support from Dee and Jimmy Haslam to fuel research and drug development for chronic lymphocytic leukaemia and other rare blood cancers.

Hematopoiesis News curates the top publications and reviews covering the regulation, expression patterns, differentiation and characterization of hematopoietic stem cells, as well as blood and bone marrow disorders. We also feature the latest job postings and upcoming conferences in the hematopoiesis field.